1. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
- Author
-
Juan Dubrot, Peter P. Du, Sarah Kate Lane-Reticker, Emily A. Kessler, Audrey J. Muscato, Arnav Mehta, Samuel S. Freeman, Peter M. Allen, Kira E. Olander, Kyle M. Ockerman, Clara H. Wolfe, Fabius Wiesmann, Nelson H. Knudsen, Hsiao-Wei Tsao, Arvin Iracheta-Vellve, Emily M. Schneider, Andrea N. Rivera-Rosario, Ian C. Kohnle, Hans W. Pope, Austin Ayer, Gargi Mishra, Margaret D. Zimmer, Sarah Y. Kim, Animesh Mahapatra, Hakimeh Ebrahimi-Nik, Dennie T. Frederick, Genevieve M. Boland, W. Nicholas Haining, David E. Root, John G. Doench, Nir Hacohen, Kathleen B. Yates, and Robert T. Manguso
- Subjects
Interferon-gamma ,Neoplasms ,Immunology ,Histocompatibility Antigens Class I ,Immunology and Allergy ,Humans ,Clustered Regularly Interspaced Short Palindromic Repeats ,CD8-Positive T-Lymphocytes ,NK Cell Lectin-Like Receptor Subfamily C ,Immune Checkpoint Inhibitors ,Immune Evasion - Abstract
The immune system can eliminate tumors, but checkpoints enable immune escape. Here, we identify immune evasion mechanisms using genome-scale in vivo CRISPR screens across cancer models treated with immune checkpoint blockade (ICB). We identify immune evasion genes and important immune inhibitory checkpoints conserved across cancers, including the non-classical major histocompatibility complex class I (MHC class I) molecule Qa-1
- Published
- 2022